Page last updated: 2024-11-10

2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3272524
CHEMBL ID222519
CHEBI ID31073
SCHEMBL ID120375
MeSH IDM0173782

Synonyms (69)

Synonym
6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide
HMS3266I19
BRD-K11796549-001-01-1
BRD-K47717570-304-01-5
NCGC00024559-01
tocris-0373
BPBIO1_001312
BIOMOL-NT_000220
nbqx
118876-58-7
2,3-dioxo-6-nitro-7-sulfamoylbenzo[f]quinoxaline
LOPAC0_000912
NCGC00024559-02
fg 9202
c12h8n4o6s
1,2,3,4-tetrahydro-6-nitro-2,3-dioxobenzo(f)quinoxaline-8-sulfonamide
6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
benzo(f)quinoxaline-7-sulfonamide, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline
fg-9202
nbqx disodium salt
chebi:31073 ,
CHEMBL222519 ,
AKOS005066691
2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo[f]quinoxaline
UQNAFPHGVPVTAL-UHFFFAOYSA-N
6-nitro-2,3-dioxo-2,3-dihydro-benzo[f]quinoxaline-7-sulfonic acid amide
6-nitro-2,3-dioxo-1,2,3,4-tetrahydro-benzo[f]quinoxaline-7-sulfinic acid amide
2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline
6-nitro-2,3-dioxo-1,2,3,4-tetrahydro-benzo[f]quinoxaline-7-sulfonic acid amide
6-nitro-2,3-dioxo-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide
2,3-dihydroxy-6-nitro-benzo[f]quinoxaline-7-sulfonic acid amide
3-hydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxalin-2-ol anion
6-nitro-2,3-dioxo-1,2,3,4,4a,10b-hexahydro-benzo[f]quinoxaline-7-sulfonic acid amide
bdbm50207594
S9686
unii-8lz6q43v2s
8lz6q43v2s ,
6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione
nbqx hydrate
FT-0621269
SBB066176 ,
AKOS015895698
6-nitro-2,3-dioxo-1h,2h,3h,4h-benzo[f]quinoxaline-7-sulfonamide
gtpl4264
SCHEMBL120375
2,3-dihydroxy-6-nitrobenzo[f]quinoxaline-7-sulfonamide
MB01584
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide
DTXSID60152256
sr-01000597617
SR-01000597617-1
HY-15068
CS-0003737
HB0442
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline -7-sulfonamide
HMS3675G09
BCP27821
HMS3411G09
Q972076
nbqx (fg9202)
BRD-K11796549-001-02-9
nbqx disodium salt hydrate
EX-A3513
AC-36382
BN167535
1,2,3,4-tetrahydro-6-nitro-2,3-dioxobenzo[f]quinoxaline-7-sulfonamide
benzo[f]quinoxaline-7-sulfonamide, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
") were also resistant to the toxic effects of quisqualic acid, indicating the possible involvement of NMDA receptors in quisqualic acid toxicity."( Quisqualic acid-induced neurotoxicity is protected by NMDA and non-NMDA receptor antagonists.
Pai, KS; Ravindranath, V, 1992
)
0.28
" Large (19-fold) increases in cortical cysteine sulphinate concentration were noted after injection of a toxic dose of cysteine."( Cysteine sulphinate and cysteate: mediators of cysteine toxicity in the neonatal rat brain?
Hagberg, H; Lehmann, A; Orwar, O; Sandberg, M, 1993
)
0.29
" However, it is unclear whether the kainate receptor itself mediates any of the toxic responses."( Cytotoxic effects of kainate ligands on HEK cell lines expressing recombinant kainate receptors.
Carver, JM; Cortes-Burgos, L; Giordano, T; Howe, JR; Mansson, PE; Shu, J; Zhou, LM, 1996
)
0.29
" Putrescine was moderately toxic but only at 500 microM concentration."( Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells.
Ciani, E; Contestabile, A; Dall'Olio, R; Gandolfi, O; Sparapani, M, 1997
)
0.3
" Our findings suggest that the toxic effects of MPP+ on dopaminergic terminals are not mediated through a direct interaction with the NMDA subtype of glutamate receptor, but with the AMPA-kainate subtype."( The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
Cano, J; Machado, A; Merino, M; Vizuete, ML, 1999
)
0.3
"Aminochrome was found to be toxic in a mouse-derived neuronal cell line (CNh)."( Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?
Armero, JM; Arriagada, C; Caviedes, P; Caviedes, R; Dagnino-Subiabre, A; Segura-Aguilar, J, 2000
)
0.31
"The potential toxic effects of the metabotropic glutamate receptor agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (ACPD) and its interactions with the N-methyl-D-aspartate (NMDA) receptor were studied in hippocampal brain slice cultures, using densitometric measurements of the cellular uptake of propidium iodide (PI) to quantify neuronal degeneration."( The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures.
Blaabjerg, M; Bonde, C; Kristensen, BW; Zimmer, J, 2001
)
0.31
"The developing cortical neurons have been well documented to be extremely vulnerable to the toxic effect of methylmercury (MeHg)."( Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity.
Arimura, K; Eto, K; Fukuyama, N; Miyamoto, K; Moriguchi, S; Murao, K; Nakanishi, H; Osame, M; Wakamiya, J, 2001
)
0.31
" The test compound used was the metabotropic glutamate receptor antagonist, L(+)-2-amino-3-phosphonopropionic acid (L-AP3), which is known to be toxic in vivo after subchronic, but not acute, administration."( Long-term, repeated dose in vitro neurotoxicity of the glutamate receptor antagonist L-AP3, demonstrated in rat hippocampal slice cultures by using continuous propidium iodide incubation.
Blaabjerg, M; Kristensen, BW; Noraberg, J; Zimmer, J, 2007
)
0.34
" Either the blockade of ionotropic glutamate NMDA-receptors with MK-801 or APV or supplementation the medium with ruthenium red (mitochondrial Ca(2+) uniporter blocker) almost entirely protected CGNs from the toxic effect of ZnCl(2) during glucose deprivation (GD)."( Glucose starvation stimulates Zn2+ toxicity in cultures of cerebellar granule neurons.
Isaev, NK; Lozier, ER; Novikova, SV; Silachev, DN; Stelmashook, EV; Zorov, DB, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" The preclinical development included pharmacokinetic and toxicological investigations in mice, rats, and dogs."( Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
Dalgaard, L; Hjortkjaer, RK; Nordholm, L; Regnier, B,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, when levetiracetam (LEV; 50mg/kg) was combined with either procyclidine (PCD; 10mg/kg) or caramiphen (CMP; 10mg/kg) complete cessation of seizures was achieved, but the nicotinic antagonist mecamylamine was needed to induce full motor rest in some rats."( Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats.
Aas, P; Enger, S; Jonassen, M; Myhrer, T, 2011
)
0.37
" In conclusion, transplants of NRP/GRP combined with NBQX promote recovery of micturition function following spinal cord injury, likely through increased neuroprotection."( Acute administration of AMPA/Kainate blocker combined with delayed transplantation of neural precursors improves lower urinary tract function in spinal injured rats.
Fischer, I; Mitsui, T; Neuhuber, B, 2011
)
0.37
"This report compares the effects on medial forebrain bundle self-stimulation of injecting into either the sublenticular central extended amygdala (SLEAc) or nucleus accumbens shell (NAcS) the D1 dopamine receptor blocker SCH23390 or the D2 dopamine receptor agonist quinpirole alone or in combination with the AMPA glutamate receptor blocker NBQX."( Comparison of the effects on brain stimulation reward of D1 blockade or D2 stimulation combined with AMPA blockade in the extended amygdala and nucleus accumbens.
Kuehn, L; Schmid, E; Stoehr, M; Waraczynski, M; Zwifelhofer, W, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" bolus followed immediately by an infusion of 10 mg/kg/h for 4 h, dosing was started immediately after MCA occlusion."( The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.
Gill, R; Lodge, D; Nordholm, L, 1992
)
0.28
" Pretreatment with glycine, an agonist to the glycine/NMDA receptors, shifted the dose-response effect of felbamate to the right (ED50 = 56."( Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994
)
0.29
" At the dosage used NBQX exerts an adverse effect."( Effects of MK-801 and NBQX on acute recovery of piglet cerebral metabolism after hypothermic circulatory arrest.
Aoki, M; Fackler, JC; Hickey, PR; Holtzman, D; Jonas, RA; Nomura, F; Stromski, ME; Tsuji, MK, 1994
)
0.29
" We, therefore, studied the dose-response characteristics and the time window of efficacy of the AMPA antagonist NBQX in a rat model of permanent focal ischemia."( A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
Chen, J; Graham, SH; Lan, JQ; Simon, RP, 1996
)
0.29
" Using the rat cortical wedge preparation, the latter series of experiments showed the expected rightward parallel shifts of the dose-response curves."( Functional partial agonism at ionotropic excitatory amino acid receptors.
Ebert, B; Krogsgaard-Larsen, P; Madsen, U; Søby, KK, 1996
)
0.29
" By comparing the increase in amplitude of the AMPA receptor response in the Bergmann glia (840 +/- 240%; n = 8) with the shift in the glutamate dose-response curve measured in excised patches (EC50, 1810 microM in control vs 304 microM in CTZ), we estimate that the extrasynaptic transmitter concentration reaches 160-190 microM."( The concentration of synaptically released glutamate outside of the climbing fiber-Purkinje cell synaptic cleft.
Dzubay, JA; Jahr, CE, 1999
)
0.3
" Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was undertaken and calcified areas (identified with Alizarin Red staining) as well as astro- and microglial reactions (by autoradiography with [3H]lazabemide and [3H]Ro 5-4864) were quantified at one month post-lesion."( Long-term effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione in the rat basal ganglia: calcification, changes in glutamate receptors and glial reactions.
Cummins, DJ; Dewar, D; Dragunow, M; Mahy, N; Petegnief, V; Saura, J, 1999
)
0.3
" Similarly, PCP dosing in rats produces typical behavioral phenotypes that mimic human schizophrenia symptoms."( Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia.
Hrupka, B; Pemberton, DJ; Pollard, M; Shaban, H; Steckler, T; Varin, C, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
sulfonic acid derivative
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.29840.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.94500.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency21.11980.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency1.41250.125919.1169125.8920AID2549
15-lipoxygenase, partialHomo sapiens (human)Potency7.94330.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
alpha-galactosidaseHomo sapiens (human)Potency31.62284.466818.391635.4813AID2107
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency15.84890.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.48130.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency100.00000.010039.53711,122.0200AID1479
DNA polymerase kappa isoform 1Homo sapiens (human)Potency16.89080.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 6Homo sapiens (human)IC50 (µMol)74.00004.00005.25006.5000AID439881
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.57810.00011.617910.0000AID257196; AID262621; AID31458; AID31580; AID92200; AID92209; AID92210; AID92348; AID92372; AID92488; AID92489; AID92495; AID92507; AID92509
Glutamate receptor 1Rattus norvegicus (Norway rat)Ki0.08830.00000.41052.7800AID92639; AID92648; AID92650; AID92777; AID92780; AID92782
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.57810.00011.700010.0000AID257196; AID262621; AID31458; AID31580; AID92200; AID92209; AID92210; AID92348; AID92372; AID92488; AID92489; AID92495; AID92507; AID92509
Glutamate receptor 2Rattus norvegicus (Norway rat)Ki0.08830.00000.68536.3000AID92639; AID92648; AID92650; AID92777; AID92780; AID92782
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)0.57810.00011.700010.0000AID257196; AID262621; AID31458; AID31580; AID92200; AID92209; AID92210; AID92348; AID92372; AID92488; AID92489; AID92495; AID92507; AID92509
Glutamate receptor 3Rattus norvegicus (Norway rat)Ki0.08830.00000.71777.4000AID92639; AID92648; AID92650; AID92777; AID92780; AID92782
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)0.57810.00011.700010.0000AID257196; AID262621; AID31458; AID31580; AID92200; AID92209; AID92210; AID92348; AID92372; AID92488; AID92489; AID92495; AID92507; AID92509
Glutamate receptor 4Rattus norvegicus (Norway rat)Ki0.08830.00000.52773.5700AID92639; AID92648; AID92650; AID92777; AID92780; AID92782
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)IC50 (µMol)2.90900.00700.98217.0000AID93118; AID93120; AID93556; AID93571; AID93715; AID93716; AID93718; AID95026
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Ki4.10000.00071.71758.1800AID93738
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki13.20000.00011.20929.9700AID239193
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)166.26670.00071.600310.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki100.00000.00030.86666.6900AID142991; AID142994
Glutamate receptor ionotropic, kainate 1Homo sapiens (human)IC50 (µMol)41.33330.07702.64425.0000AID262631; AID281130; AID281131
Glutamate receptor ionotropic, kainate 1Homo sapiens (human)Ki11.73000.00071.75084.8000AID239192
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)IC50 (µMol)2.90900.00701.01327.0000AID93118; AID93120; AID93556; AID93571; AID93715; AID93716; AID93718; AID95026
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Ki4.10000.00370.80254.1000AID93738
Glutamate receptor 1Homo sapiens (human)IC50 (µMol)6.00000.01901.70836.5100AID262640
Glutamate receptor 1Homo sapiens (human)Ki1.60000.01472.50379.2000AID92950
Glutamate receptor 2Homo sapiens (human)IC50 (µMol)2.50000.01901.64035.5000AID262641; AID281129
Glutamate receptor 2Homo sapiens (human)Ki0.23500.01681.27725.0000AID239622; AID92961
Glutamate receptor 3Homo sapiens (human)IC50 (µMol)1.90000.01901.13424.8000AID262642
Glutamate receptor 3Homo sapiens (human)Ki0.90000.02060.53222.2000AID93101
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)IC50 (µMol)2.90900.00701.01327.0000AID93118; AID93120; AID93556; AID93571; AID93715; AID93716; AID93718; AID95026
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Ki4.10000.00380.79754.1000AID93738
Glutamate receptor 4Homo sapiens (human)IC50 (µMol)1.10000.01901.22234.8000AID262643
Glutamate receptor 4Homo sapiens (human)Ki0.60000.04001.23358.8500AID93110
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki13.20000.00000.437510.0000AID239193
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)99.52000.00071.630610.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki100.00000.00030.68056.6900AID142991; AID142994
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)99.52000.00061.525710.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki100.00000.00030.70716.6900AID142991; AID142994
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)99.52000.00071.747210.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki100.00000.00030.81966.6900AID142991; AID142994
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)IC50 (µMol)2.90900.00701.01327.0000AID93118; AID93120; AID93556; AID93571; AID93715; AID93716; AID93718; AID95026
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)Ki4.10000.00471.59194.1000AID93738
Glutamate receptor ionotropic, kainate 2Homo sapiens (human)IC50 (µMol)29.00000.07700.07700.0770AID262638; AID281133
Glutamate receptor ionotropic, kainate 2Homo sapiens (human)Ki42.13330.00120.33441.1060AID239193; AID93403; AID93404
Glutamate receptor ionotropic, kainate 3Homo sapiens (human)IC50 (µMol)44.00000.07702.03854.0000AID257203
Glutamate receptor ionotropic, kainate 3Homo sapiens (human)Ki18.00000.01000.39950.7890AID257203
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)99.52000.00071.741110.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki100.00000.00030.70726.6900AID142991; AID142994
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)IC50 (µMol)2.90900.00701.01327.0000AID93118; AID93120; AID93556; AID93571; AID93715; AID93716; AID93718; AID95026
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)Ki4.10000.01501.59454.1000AID93738
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)99.52000.00071.741110.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki100.00000.00030.70726.6900AID142991; AID142994
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)99.52000.00071.741110.0000AID143295; AID143306; AID143474; AID143613; AID144764; AID144899; AID145038; AID496836; AID496837
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki100.00000.00030.70726.6900AID142991; AID142994
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Kd1.78000.01801.27203.9400AID257198
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)Kd1.78000.40201.09101.7800AID262620
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Activity0.15000.10500.15830.2200AID31451
Glutamate receptor 1Rattus norvegicus (Norway rat)Kb2.00000.59003.33007.0000AID477155
Glutamate receptor 2Rattus norvegicus (Norway rat)Activity0.15000.10500.18630.2700AID31451
Glutamate receptor 2Rattus norvegicus (Norway rat)Kb0.59000.59003.17337.0000AID477156
Glutamate receptor 3Rattus norvegicus (Norway rat)Activity0.15000.10500.15830.2200AID31451
Glutamate receptor 3Rattus norvegicus (Norway rat)Kb0.63000.59003.17787.0000AID477157
Glutamate receptor 4Rattus norvegicus (Norway rat)Activity0.15000.10500.15830.2200AID31451
Glutamate receptor 4Rattus norvegicus (Norway rat)Kb1.60000.59003.28567.0000AID477158
Glutamate receptor 1Homo sapiens (human)Kb0.27750.16600.42201.0000AID477143; AID477148; AID477151; AID477153
Glutamate receptor 2Homo sapiens (human)Kb0.16600.16600.34400.7000AID477148; AID477153
Glutamate receptor 4Homo sapiens (human)Kb0.10200.10200.10200.1020AID477144
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (66)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 6Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 6Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 6Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 6Homo sapiens (human)
detection of visible lightMetabotropic glutamate receptor 6Homo sapiens (human)
detection of light stimulus involved in visual perceptionMetabotropic glutamate receptor 6Homo sapiens (human)
retina development in camera-type eyeMetabotropic glutamate receptor 6Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 6Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
central nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of receptor recyclingGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synapse assemblyGlutamate receptor 1Homo sapiens (human)
long-term memoryGlutamate receptor 1Homo sapiens (human)
response to xenobiotic stimulusGlutamate receptor 1Homo sapiens (human)
response to lithium ionGlutamate receptor 1Homo sapiens (human)
positive regulation of gene expressionGlutamate receptor 1Homo sapiens (human)
neuronal action potentialGlutamate receptor 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 1Homo sapiens (human)
spinal cord developmentGlutamate receptor 1Homo sapiens (human)
cerebral cortex developmentGlutamate receptor 1Homo sapiens (human)
receptor internalizationGlutamate receptor 1Homo sapiens (human)
response to estradiolGlutamate receptor 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 1Homo sapiens (human)
response to cocaineGlutamate receptor 1Homo sapiens (human)
positive regulation of membrane potentialGlutamate receptor 1Homo sapiens (human)
response to arsenic-containing substanceGlutamate receptor 1Homo sapiens (human)
response to electrical stimulusGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 1Homo sapiens (human)
long-term synaptic depressionGlutamate receptor 1Homo sapiens (human)
response to fungicideGlutamate receptor 1Homo sapiens (human)
cellular response to amino acid stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to ammonium ionGlutamate receptor 1Homo sapiens (human)
cellular response to dsRNAGlutamate receptor 1Homo sapiens (human)
cellular response to peptide hormone stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to amine stimulusGlutamate receptor 1Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusGlutamate receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 2Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
protein homotetramerizationGlutamate receptor 3Homo sapiens (human)
protein heterotetramerizationGlutamate receptor 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 4Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processGlutamate receptor 4Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 4Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 4Homo sapiens (human)
behavioral fear responseGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
intracellular calcium ion homeostasisGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
neuronal action potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
receptor clusteringGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
negative regulation of neuron apoptotic processGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
positive regulation of neuron apoptotic processGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
regulation of JNK cascadeGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
regulation of long-term neuronal synaptic plasticityGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
regulation of short-term neuronal synaptic plasticityGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
positive regulation of synaptic transmissionGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
neuron apoptotic processGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
inhibitory postsynaptic potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
modulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
detection of cold stimulus involved in thermoceptionGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 6Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
protein homodimerization activityMetabotropic glutamate receptor 6Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 1Homo sapiens (human)
G-protein alpha-subunit bindingGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
protein bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
adenylate cyclase bindingGlutamate receptor 1Homo sapiens (human)
immunoglobulin bindingGlutamate receptor 1Homo sapiens (human)
protein kinase bindingGlutamate receptor 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 1Homo sapiens (human)
PDZ domain bindingGlutamate receptor 1Homo sapiens (human)
small GTPase bindingGlutamate receptor 1Homo sapiens (human)
myosin V bindingGlutamate receptor 1Homo sapiens (human)
G-protein beta-subunit bindingGlutamate receptor 1Homo sapiens (human)
beta-2 adrenergic receptor bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor bindingGlutamate receptor 1Homo sapiens (human)
identical protein bindingGlutamate receptor 1Homo sapiens (human)
protein kinase A bindingGlutamate receptor 1Homo sapiens (human)
scaffold protein bindingGlutamate receptor 1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
protein bindingGlutamate receptor 2Homo sapiens (human)
ligand-gated monoatomic cation channel activityGlutamate receptor 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 3Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 4Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 4Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
SNARE bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
extracellularly glutamate-gated ion channel activityGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
PDZ domain bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
ubiquitin conjugating enzyme bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
ubiquitin protein ligase bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
scaffold protein bindingGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
Golgi membraneMetabotropic glutamate receptor 6Homo sapiens (human)
endoplasmic reticulum membraneMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
dendriteMetabotropic glutamate receptor 6Homo sapiens (human)
new growing cell tipMetabotropic glutamate receptor 6Homo sapiens (human)
synapseMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
intracellular membrane-bounded organelleGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
cell-cell junctionGlutamate receptor 1Homo sapiens (human)
cell surfaceGlutamate receptor 1Homo sapiens (human)
ER to Golgi transport vesicle membraneGlutamate receptor 1Homo sapiens (human)
postsynaptic densityGlutamate receptor 1Homo sapiens (human)
dendriteGlutamate receptor 1Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 1Homo sapiens (human)
synaptic vesicle membraneGlutamate receptor 1Homo sapiens (human)
neuromuscular junctionGlutamate receptor 1Homo sapiens (human)
early endosome membraneGlutamate receptor 1Homo sapiens (human)
dendritic spine membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell body membraneGlutamate receptor 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell bodyGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
dendritic shaftGlutamate receptor 1Homo sapiens (human)
axonal spineGlutamate receptor 1Homo sapiens (human)
neuron spineGlutamate receptor 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor 1Homo sapiens (human)
presynaptic active zone membraneGlutamate receptor 1Homo sapiens (human)
recycling endosomeGlutamate receptor 1Homo sapiens (human)
recycling endosome membraneGlutamate receptor 1Homo sapiens (human)
excitatory synapseGlutamate receptor 1Homo sapiens (human)
synaptic membraneGlutamate receptor 1Homo sapiens (human)
presynapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
glutamatergic synapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density, intracellular componentGlutamate receptor 1Homo sapiens (human)
perisynaptic spaceGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
external side of plasma membraneGlutamate receptor 2Homo sapiens (human)
postsynaptic densityGlutamate receptor 2Homo sapiens (human)
dendriteGlutamate receptor 2Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 2Homo sapiens (human)
asymmetric synapseGlutamate receptor 2Homo sapiens (human)
neuronal cell bodyGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
excitatory synapseGlutamate receptor 2Homo sapiens (human)
postsynapseGlutamate receptor 2Homo sapiens (human)
postsynaptic endocytic zoneGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic membraneGlutamate receptor 3Homo sapiens (human)
parallel fiber to Purkinje cell synapseGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 3Homo sapiens (human)
dendritic spineGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendriteGlutamate receptor 4Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 4Homo sapiens (human)
neuronal cell bodyGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
extracellular vesicleGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 4Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 4Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
dendrite cytoplasmGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
perikaryonGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
mossy fiber rosetteGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 2Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
axonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
dendriteGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
dendrite cytoplasmGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
perikaryonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (153)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID252285Effect on brain lesion measured 24 hour after permanent MCA occlusion in mice upon three i.p. doses of 30 mg/kg (n=12)2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
AID93715Inhibition concentration towards high-affinity ionotropic glutamate receptor kainate of rat cortical membranes by using [3H]KA as radioligand2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID132057Effective dose of the intraperitoneally administered compound required to protect 50% of mice from tonic convulsion caused by maximal electric shock (MES)2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
AID477158Antagonist activity at rat recombinant GluA4 receptor flip isoform expressed in HEK293 cells assessed as effect on cyclothiazide-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID262620Antagonist activity against GLUK5-containing kainate receptor by inhibition of kainate-induced depolarization of neonatal rat dorsal root fibers2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID670593Neuroprotective activity in organotypic Wistar rat hippocampal CA1 region slices assessed as protection from oxygen-deprivation-induced neuronal damage at 30 uM dosed during 30 mins insult and subsequent 24 hrs recovery period by propidium iodide staining2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID234757Selectivity between AMPA/kainate receptor and NMDA/glycine receptor1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID281129Antagonist activity at human recombinant GLUA2-AMPA receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID145038Inhibition of [3H]CPP binding to rat N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID143306Binding affinity for N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
AID496834Displacement of [3H]AMPA from AMPA receptor in rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID239234Inhibition of [3H]KA binding to human iontropic glutamate receptors 5 and 62005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID143457Ratio of binding affinity towards N-methyl-D-aspartate glutamate receptor (NMDA-R) to that of AMPA-R2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position.
AID142994The compound was tested for its ability to inhibit [3H]Gly binding to N-methyl-D-aspartate glutamate receptor from rat whole brain.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
AID91447Compound was tested or its affinity against ionotropic glutamate receptor ionotropic kainate in rats was determined at a concentration of 100 uM1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID92348Binding affinity for Ionotropic glutamate receptor AMPA2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
AID262633Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK2 by FLIPR assay2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID477149Antagonist activity at recombinant GluA2A4 receptor flip isoform expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID93101Ability to displace binding of [3H]AMPA to recombinant human Ionotropic glutamate receptor AMPA 32002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID92197Antagonism of Ionotropic glutamate receptor AMPA action was measured as [Ca2+] influx in rat cerebellar granule neurons at 1 uM concentration1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
AID93571Compound was evaluated for inhibition of binding of [3H]KA to specific binding at Ka receptor in rat cortical membrane2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
AID196109The compound was tested for anti-KA-Induced Neurotoxicity in rat primary hippocampal cultures.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
AID262639Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK6/GLUK22006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID262641Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA22006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID93256Ability to displace binding of [3H]AMPA to recombinant human Ionotropic glutamate receptor ionotropic kainate 12002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID93120Inhibitory activity against [3H]AMPA binding to rat cortical membranes1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID169555Neuroprotective effect in rat after iv administration at a dose of 30 mg/kg/h for 4 h2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position.
AID239255Inhibition of [3H]KA binding to human iontropic glutamate receptors 6 and KA-22005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID257203Displacement of [3H]kainate from human GLUK7 receptor expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID281122Antagonist activity at native AMPA receptor assessed as fDR-VRP reduction of neonatal rat spinal cord motorneurones2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID92343Binding affinity in rat brain cortical membranes by the displacement of [3H]AMPA at Ionotropic glutamate receptor AMPA1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
AID132520Concentration necessary for 50% inhibition of depolarization induced by 5 uM S-AMPA in mouse cortical wedge preparation2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID239193Inhibition of [3H]KA binding to iontropic glutamate receptor 62005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID477150Selectivity ratio of Kb for recombinant GluA1A2 receptor flip isoform to Kb for recombinant GluA2A4 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID281132Antagonist activity at human recombinant GLUK5/GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID144764In vitro binding affinity towards NMDA glutamate receptor using [3H]5,7-dichlorokynurenate as ligand on rat cortical membrane preparations2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
AID143474Antagonistic activity against N-methyl-D-aspartate glutamate receptor 1 in Xenopus oocytes1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID93738Binding affinity towards Ionotropic glutamate receptor kainate was determined in rat cortical membrane using [3H]KA as radioligand1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
AID92782The compound was tested for its ability to inhibit [3H]AMPA binding to Ionotropic glutamate receptor AMPA from rat whole brain1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
AID113961Anticonvulsant activity in male CD1 mice2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
AID262642Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA32006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID142991The compound was tested for its ability to inhibit [3H]Glu binding to N-methyl-D-aspartate glutamate receptor from rat whole brain.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
AID477143Antagonist activity at recombinant GluA1 receptor expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477151Antagonist activity at recombinant GluA1 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477157Antagonist activity at rat recombinant GluA3 receptor flip isoform expressed in HEK293 cells assessed as effect on cyclothiazide-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID93556Antagonistic activity against Ionotropic glutamate receptor kainate induced LDH release in cultured cortical neurons in rat after 24 hr application of 500 uM of kainate1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID92209Antagonistic activity against Ionotropic glutamate receptor AMPA induced LDH release in cultured rat cortical neurons after 24 hr 100 uM AMPA1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID132325Ability to inhibit depolarizations induced by AMPA in mouse cortical wedge preparations2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
AID143625Percent inhibition of compound at 100 uM towards N-methyl-D-aspartate glutamate receptor 1 (high affinity) of rat cortical synaptic membranes by using [3H]-Gly as radioligand2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID262632Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK6 by FLIPR assay2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID145176Inhibition of [3H]- glycine binding to NMDA receptor of rat membrane2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.
AID73798Compound was evaluated for inhibition of binding of [3H]glycine to specific binding at glycine receptor in rat cortical membrane at 100 uM2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
AID92780Inhibitory concentration of compound for depolarization induced by 5 uM S-AMPA in mouse cortical wedge preparation2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists.
AID326374Inhibition of kainate-induced C57BL/6N mouse hippocampal neurons excitotoxicity after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent.
AID114039Mouse maximum electroshock induced test seizure test in mice1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
AID114293Antinociceptive activity of tail flick test in mice, when administarted intrathecally1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
AID143613Inhibitory activity against [3H]glycine binding site of N-methyl-D-aspartate glutamate receptor 1 in rat cortical membranes1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID145120Binding affinity of compound against NMDA receptor binding site in rat brain membrane using [3H]glutamate as radioligand1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
AID92352Binding affinity was determined against ionotropic glutamate receptor AMPA in rat brain synaptic membranes using [3H]AMPA as radioligand1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID670586Displacement of [3H](+)MK-801 from N-methyl D-aspartate receptor in rat cortical membrane2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID239622Inhibition of [3H]-AMPA binding to human GluR2 receptors expressed in HEK 293 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID262643Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA42006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID31458Antagonist potency against functional AMPA receptor by kainate-induced Ca+2 in rat cerebellar granule neurons in primary culture2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists.
AID477155Antagonist activity at rat recombinant GluA1 receptor flip isoform expressed in HEK293 cells assessed as effect on cyclothiazide-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID31580Inhibitory activity against AMPA receptor currents in rat cortical cells stimulated with 50 uM kainic acid1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor.
AID92644Binding affinity towards Ionotropic glutamate receptor AMPA was determined in rat whole brain membrane using [3H]AMPA as radioligand1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
AID132519Concentration necessary for 50% inhibition of depolarization induced by 5 uM NMDA in mouse cortical wedge preparation2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID179380Concentration of compound that inhibits by 50% LDH released by 24 hr application of 100 uM AMPA1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID281130Antagonist activity at human recombinant GLUK5 receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID92643Binding affinity for ionotropic glutamate receptor AMPA using [3H]AMPA as radioligand, bound to synaptic membranes prepared from rat cerebral cortex2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position.
AID670580Displacement of [3H]AMPA from AMPA receptor in rat cortical synaptical membrane2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID272855Antagonist activity against AMPA receptor assessed as inhibition of SAMPA-induced depolarization of mouse cortex2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies.
AID93404Ability to displace binding of [3H]KA to recombinant human KA receptor Ionotropic glutamate receptor ionotropic kainate 2 expressed in EK 293 cell membranes2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID670588Antagonist activity at AMPA receptor in mouse cortical wedge assessed as inhibition of S-AMPA-induced membrane depolarization by electrophysiological assay2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID143607Affinity for N-methyl-D-aspartate glutamate receptor 1 in rat brain synaptic membranes, using [3H]glycine as radioligand1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID92507The compound was tested for its affinity against AMPA receptor in rats1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID92488Inhibition of Ca 2+ Influx in cultured rat cerebellar granule cells, mediated by ionotropic glutamate receptor AMPA2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether.
AID281133Antagonist activity at human recombinant GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID93716Inhibition concentration towards low-affinity Ionotropic glutamate receptor kainate of rat cortical membranes by using [3H]-KA as radioligand2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID93567Binding affinity for the ionotropic glutamate receptor kainate in rat brain synaptic membranes using [3H]kainate as radioligand1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID92950Ability to displace binding of [3H]AMPA to recombinant human Ionotropic glutamate receptor AMPA 12002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID144184Agonistic activity at N-methyl-D-aspartate glutamate receptor was measured as [Ca2+] influx in rat cerebellar granule neurons at 10 uM concentration1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
AID670583Displacement of [3H]glycine from NMDA receptor in rat cortical synaptical membrane at 100 uM2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID93718Inhibition of [3H]KA binding to kainate receptor of rat brain membranes2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.
AID439881Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Substituted 2-aminothiopen-derivatives: a potential new class of GluR6-antagonists.
AID477153Antagonist activity at recombinant GluA1A2 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID143295Displacement of [3H]DCKA from N-methyl-D-aspartate glutamate receptor of rat cortical membrane2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
AID223293Dose which protected 50 % of the mice from a tonic convulsion.2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
AID257196Antagonist activity on AMPA receptor expressed on rat motoneurons by its ability to reduce the fast component dorsal root evoked ventral root potential (fDR-VRP)2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID496839Neuroprotective effect against middle cerebral artery occlusion-induced focal cerebral ischemia in iv dosed spontaneously hypertensive rat2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID262640Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA12006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID114202Effective dose required to protect 50% of DBA/2 mice from audiogenic seizures, after ip administration1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID92961Ability to displace binding of [3H]AMPA to recombinant human Ionotropic glutamate receptor AMPA 22002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID92777Displacement binding affinity against Ionotropic glutamate receptor AMPA was determined2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists.
AID92372Affinity towards Ionotropic glutamate receptor AMPA using [3H]AMPA as ligand on rat cortical membrane preparations2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
AID92509Displacement of [3H]AMPA from Ionotropic glutamate receptor AMPA of rat cortical membranes2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
AID31451Tested for in vitro binding affinity against AMPA receptor using [3H]AMPA binding assay1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
5-Aminomethylquinoxaline-2,3-diones. Part I: A novel class of AMPA receptor antagonists.
AID143302Binding affinity towards glycine binding site on NMDA receptor was determined in rat whole brain membrane using strychnine-insensitive [3H]Gly as radioligand1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
AID92648Binding affinity towards ionotropic glutamate receptor (high-affinity) of rat cortical synaptic membranes by using [3H]AMPA as radioligand2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID257198Antagonism on GLUK5 containing kainate induced depolarization of isolated neonatal rat dorsal root C-fibers2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID93736Binding affinity against kainate receptor in rat brain membrane using [3H]kainate as radioligand1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
AID477156Antagonist activity at rat recombinant GluA2 receptor flip isoform expressed in HEK293 cells assessed as effect on cyclothiazide-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477152Antagonist activity at recombinant GluA4 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID239192Inhibition of [3H]-KA binding to iontropic glutamate receptor 52005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID95026Inhibitory activity against generation of currents by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
AID670589Antagonist activity at NMDA receptor in mouse cortical wedge assessed as inhibition of NMDA-induced membrane depolarization at 10 uM by electrophysiological assay2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID145121Binding affinity of compound against strychnine-insensitive glycine site on NMDA receptor in rat brain membrane using [3H]glycine as radioligand1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
AID75115%Protection against transient global ischemia in adult Mongolian gerbil at dose 30 mg/kg by ip administration tested against 61996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID179381Concentration of compound that inhibits by 50% LDH released by 24 hr application of 500 uM kainate1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID496837Inhibition of NMDA receptor glycine site from rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID31606Binding affinity against AMPA receptor in rat brain membrane using [3H]-AMPA as radioligand1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
AID496840Anticonvulsant activity in ip dosed DBA2 mouse assessed as inhibition of sound-induced clonic seizures2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID239254Inhibition of [3H]KA binding to human iontropic glutamate receptors 5 and KA-22005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
AID92210Antagonistic activity against Ionotropic glutamate receptor AMPA using kainate-evoked current in Xenopus oocytes injected with rat brain mRNA2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
AID262631Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5 by FLIPR assay2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID145322Binding affinity towards NMDA receptor was determined in rat whole brain membrane using NMDA-sensitive [3H]Glu as radioligand1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
AID114021Effective dose of a compound to produce 50% audiogenic seizures in DBA/2 mice when administered by po (mg/kg); Not active1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID496838Selectivity ratio IC50 for rat AMPA receptor to IC50 rat kainate receptor2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID496835Displacement of [3H]kainate from kainate receptor in rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID143626Percentage inhibition of [3H]glycine to NMDA receptors of rat cortical membranes at 32 uM2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists.
AID477148Antagonist activity at recombinant GluA1A2 receptor flip isoform expressed in Xenopus oocytes assessed as inhibition of glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID132055Effective dose of the intraperitoneally administered compound required to protect 50% of DBA/2 mice from tonico-clonic convulsion2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
AID93403Ability to displace binding of [3H]AMPA to recombinant human AMPA receptor Ionotropic glutamate receptor ionotropic kainate 22002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID92650Compound was evaluated for inhibition of binding of [3H]AMPA to specific binding at Ionotropic glutamate receptor AMPA in rat cortical membrane2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
AID179382Concentration of compound that inhibits by 50% depolarizations induced by 10 uM AMPA1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID477154Antagonist activity at recombinant GluA2A4 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID31590Inhibition of kainic acid induced AMPA receptor mediated current at 100 uM1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor.
AID92495Inhibition of binding of [3H]AMPA to the binding sites of Ionotropic glutamate receptor AMPA in rat cortical membranes, at 32 uM conc.2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists.
AID229290Ratio of IC50 of KA low-affinity receptor site to KA high-affinity receptor site2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID144899Inhibition of [3H]-(+)-MK-801 binding to NMDA receptor ion-channel complex of rat cortical memembranes2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.
AID92639Binding affinity at ionotropic glutamate receptor AMPA in rat cortical membranes [3H]AMPA displacement.2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.
AID477144Antagonist activity at recombinant GluA4 receptor expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID92200Ability to block kainate-induced 45 [Ca2+] influx through functional assay of Ionotropic glutamate receptor AMPA activity in rat cerebellar granule cells.2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists.
AID93410Ability to displace binding of [3H]AMPA to recombinant human AMPA receptor Ionotropic glutamate receptor ionotropic kainate 32002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID179379Concentration giving 50% inhibition of stimulated [3H](+)-MK-801 binding in rat cortical membranes incubated with 10 uM glycine2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID477145Selectivity ratio of Kb for recombinant GluA1 receptor to Kb for recombinant GluA4 receptor expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID670584Displacement of [3H]kainate from high affinity kainate receptor in rat cortical membrane2012European journal of medicinal chemistry, Aug, Volume: 543-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.
AID262621Antagonist activity against AMPA receptor expressed in motoneurones by inhibition of fDR-VRP in the neonatal rat spinal cord2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID93548Antagonism of Ionotropic glutamate receptor kainate action was measured as [Ca2+] influx in rat cerebellar granule neurons at 10 uM concentration1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
AID262638Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK62006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
AID93110Ability to displace binding of [3H]AMPA to recombinant human Ionotropic glutamate receptor AMPA 42002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
AID179408Concentration that inhibits 50% S-AMPA stimulated (50 uM) [3H]norepinephrine release from rat hippocampal synaptosomes2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
AID145114Inhibitory concentration of compound for depolarization induced by 5 uM concentration; NS indicates not significant2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists.
AID281134Antagonist activity at human recombinant GLUK6/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
AID92489Inhibition of Ionotropic glutamate receptor AMPA induced depolarization in rat cortical wedge by application of 10 uM of AMPA1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant act
AID75113%Protection against transient global ischemia in adult Mongolian gerbil at dose 10 mg/kg by ip administration tested against 101996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID93118Antagonistic activity against rat ionotropic glutamate receptor ionotropic kainate in xenopus oocytes1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
AID184018In vitro inhibitory effect on AMPA-induced DC potential in rat cortical slices; Not tested2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position.
AID132327Ability to inhibit depolarizations induced by NMDA in mouse cortical wedge preparations at 10 uM; not tested2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.
AID496836Inhibition of NMDA receptor glutamate site from rat cortical membrane2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID281131Antagonist activity at human recombinant GLUK5/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,198)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's456 (38.06)18.2507
2000's481 (40.15)29.6817
2010's246 (20.53)24.3611
2020's15 (1.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.25 (24.57)
Research Supply Index7.10 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (0.58%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,209 (99.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]